Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert R Henry

Showing results (41-50 of 155) with videos related to

Pageof 16
Sort By:
JAAPA : Official Journal of the American Academy of Physician Assistants|March 16, 2007
Cardiometabolic risk modification: current trends and emerging therapiesJoseph L Lillo, George Bray, Stephen C Woods, et al.
Lancet (London, England)|June 12, 2009
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyRobert R Henry, A Michael Lincoff, Sunder Mudaliar, et al.
Journal of Diabetes and Its Complications|March 18, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetesRobert R Henry, Julio Rosenstock, Douglas Logan, et al.
Diabetes|July 29, 2003
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reductionYoung-Bum Kim, Ko Kotani, Theodore P Ciaraldi, et al.
Metabolism: Clinical and Experimental|August 30, 2002
Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjectsTheodore P Ciaraldi, Leslie Carter, Nabeela Rehman, et al.
Diabetes Care|April 12, 2014
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?Alex M DePaoli, Linda S Higgins, Robert R Henry, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 30, 2019
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?Robert H Eckel, Azeez Farooki, Robert R Henry, et al.
Adipocyte|September 21, 2013
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesityLauren K Meyer, Theodore P Ciaraldi, Robert R Henry, et al.
The Journal of Clinical Endocrinology and Metabolism|June 5, 2013
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteersRobert R Henry, Theodore P Ciaraldi, Debra Armstrong, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor ITheodore P Ciaraldi, Susan A Phillips, Leslie Carter, et al.
Pageof 16

Showing results (41-50 of 155) with videos related to

Sort By:
Pageof 16
JAAPA : Official Journal of the American Academy of Physician Assistants|March 16, 2007
Cardiometabolic risk modification: current trends and emerging therapiesJoseph L Lillo, George Bray, Stephen C Woods, et al.
Lancet (London, England)|June 12, 2009
Effect of the dual peroxisome proliferator-activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised, dose-ranging studyRobert R Henry, A Michael Lincoff, Sunder Mudaliar, et al.
Journal of Diabetes and Its Complications|March 18, 2014
Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetesRobert R Henry, Julio Rosenstock, Douglas Logan, et al.
Diabetes|July 29, 2003
Insulin-stimulated protein kinase C lambda/zeta activity is reduced in skeletal muscle of humans with obesity and type 2 diabetes: reversal with weight reductionYoung-Bum Kim, Ko Kotani, Theodore P Ciaraldi, et al.
Metabolism: Clinical and Experimental|August 30, 2002
Insulin and insulin-like growth factor-1 action on human skeletal muscle: preferential effects of insulin-like growth factor-1 in type 2 diabetic subjectsTheodore P Ciaraldi, Leslie Carter, Nabeela Rehman, et al.
Diabetes Care|April 12, 2014
Can a selective PPARγ modulator improve glycemic control in patients with type 2 diabetes with fewer side effects compared with pioglitazone?Alex M DePaoli, Linda S Higgins, Robert R Henry, et al.
Clinical Diabetes : a Publication of the American Diabetes Association|October 30, 2019
Cardiovascular Outcome Trials in Type 2 Diabetes: What Do They Mean for Clinical Practice?Robert H Eckel, Azeez Farooki, Robert R Henry, et al.
Adipocyte|September 21, 2013
Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesityLauren K Meyer, Theodore P Ciaraldi, Robert R Henry, et al.
The Journal of Clinical Endocrinology and Metabolism|June 5, 2013
Hyperglycemia associated with pasireotide: results from a mechanistic study in healthy volunteersRobert R Henry, Theodore P Ciaraldi, Debra Armstrong, et al.
The Journal of Clinical Endocrinology and Metabolism|July 21, 2005
Effects of the rapid-acting insulin analog glulisine on cultured human skeletal muscle cells: comparisons with insulin and insulin-like growth factor ITheodore P Ciaraldi, Susan A Phillips, Leslie Carter, et al.
Pageof 16